Recent Updates
Recently added Catalysts

V116

Phase 3

Pneumococcal Disease | Monoclonal antibody | Infectious Disease |Merck & Company, Inc.|Last Updated: Mar 11, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials4
Total Enrollment4,409

FDA Designations

No designations recorded

Clinical trial landscape

V116 · 11 trials · 3 indications

Phase 3 9Phase 1 2
NCT06177912A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)Pneumococcal Infection
COMPLETED882 Analytics
NCT05696080Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)Pneumococcal Infection
COMPLETED518 Analytics
NCT05633992Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)Pneumococcal Disease
COMPLETED450 Analytics
NCT05569954Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)Pneumococcal Disease
COMPLETED1,484 Analytics
NCT05526716A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)Pneumonia, Pneumococcal
COMPLETED1,080 Analytics
NCT05464420A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)Pneumococcal Disease
COMPLETED2,162 Analytics
NCT05393037Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)Pneumococcal Disease
COMPLETED313 Analytics
NCT05425732Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)Pneumococcal Infection
COMPLETED2,663 Analytics
NCT05420961A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)Pneumonia, Pneumococcal
COMPLETED717 Analytics
PHASE3COMPLETED
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Pneumococcal InfectionUnlock trial analytics
PHASE3COMPLETED
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
Pneumococcal InfectionUnlock trial analytics
PHASE3COMPLETED
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
Pneumococcal DiseaseUnlock trial analytics
PHASE3COMPLETED
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
Pneumococcal DiseaseUnlock trial analytics
PHASE3COMPLETED
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
Pneumonia, PneumococcalUnlock trial analytics
PHASE3COMPLETED
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
Pneumococcal DiseaseUnlock trial analytics
PHASE3COMPLETED
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
Pneumococcal DiseaseUnlock trial analytics
PHASE3COMPLETED
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
Pneumococcal InfectionUnlock trial analytics
PHASE3COMPLETED
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
Pneumonia, PneumococcalUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Up to 5 days postvaccination

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling.

Percentage of Participants With Solicited Systemic AEs
Up to 5 days post vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included muscle aches all over the body (myalgia), headache, tiredness (fatigue), hives or welts (urticaria), irritability, joint pain (arthralgia), drowsiness (somnolence), feeling sick (malaise), and fever (pyrexia).

Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
Up to approximately 6 months

A vaccine-related SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.

Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Responses
30 days postvaccination

Opsonophagocytic activity (OPA) for the serotypes in V116 will be determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination
Up to 5 days following each vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs was assessed following any vaccination. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.

Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccination
Up to 5 days following each vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature \>= 100.4 °F/38.0 °C).

Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study
Up to 194 days following Visit 2 (Day 1)

A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, which is determined by the investigator to be related to the vaccine. The percentage of participants with SAEs was assessed following any vaccination.

Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116
30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.

The serotype specific OPA GMTs for the pneumococcal serotypes were determined using the multiplex opsonophagocytic assay (MOPA). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Percentage of Participants With Vaccine-related Serious AEs (SAEs)
Up to 30 days postvaccination

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.

Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)
Day 30 postvaccination

The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).

Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)
Baseline (Day 1) and Day 30 postvaccination

The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.

Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116
Day 30 postvaccination

Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116
Baseline (Day 1) and Day 30 postvaccination

The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

Number of Participants With Solicited Injection-site Adverse Events (AEs)
Up to 5 days post-vaccination

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included erythema, pain, and swelling.

Number of Participants With Solicited Systemic AEs
Up to 5 days post-vaccination

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include fatigue, headache, myalgia, and pyrexia.

Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses
30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)

OPA for the serotypes in V116 were determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs (GMTs) (estimated) and GMT ratios with 95% CIs were calculated using a constrained longitudinal data analysis (cLDA) model utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.

GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)
Day 30

GMTs for the 4 strains contained in QIV vaccine were determined using an HAI assay.

Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots
Up to 5 days

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23
Up to 5 days

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 Lots
Up to 5 days

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23
Up to 5 days

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.

Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots
Up to 194 days

An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23
Up to 194 days

An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per the statistical analysis plan, no within group MOD were planned or calculated.

Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Day 30

Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.

Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A
Up to 5 days after each vaccination in Part A

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.

Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A
Up to 5 days after each vaccination in Part A

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.

Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A
Up to 194 days in Part A

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed.

Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Up to 114 days

Serotype-specific OPA to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

Percentage of Participants With Vaccine-related Serious AE (SAE)
Up to 194 days post-vaccination

A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event, which is determined by the investigator to be related to the vaccine.

Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20
Day 30 post-vaccination

The serotype specific OPA GMTs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using the multiplex opsonophagocytic assay (MOPA). GMT values were estimated from a constrained longitudinal data analysis; (cLDA) model. Per protocol, within group, confidence intervals (CIs) or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116
Baseline and Day 30 post-vaccination

The percentage of participants with ≥4-fold rise from baseline in serotype specific OPAs for the 11 unique pneumococcal serotypes contained in V116. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.

Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116
Day 30 post-vaccination

The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA. GMT values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.

Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)
30 Days post-vaccination

OPA for the serotypes contained in V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
Up to 5 days postvaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.

Percentage of Participants With a Solicited Systemic AE
Up to 5 days postvaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.

Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)
Up to 62 days postvaccination

An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.

Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
Up to 5 days post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

Phase 1: Percentage of Participants With a Solicited Systemic AE
Up to 5 days post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was assessed.

Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
Up to Day 195

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

Phase 2: Percentage of Participants With a Solicited Injection-site AE
Up to 5 days post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

Phase 2: Percentage of Participants With a Solicited Systemic AE
Up to 5 days post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with 1 or more solicited systemic AE was assessed.

Phase 2: Percentage of Participants With Vaccine-related SAEs
Up to Day 293

An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced at least one SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23
30 days post vaccination

GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the muliplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.

Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116
30 days post vaccination

GMTs for the serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Secondary Endpoints

Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) After Vaccination
30 days postvaccination
Geometric Mean Fold Rise (GMFR) From Baseline in Serotype-specific OPA GMTs
Baseline (Day 1) and 30 days postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs GMTs
Baseline (Day 1) and Day 30 postvaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
V116EXPERIMENTALParticipants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1
PPSV23ACTIVE_COMPARATORParticipants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
V116 + PlaceboEXPERIMENTALParticipants administered a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo on Week 8.
PCV15 + PPSV23ACTIVE_COMPARATORParticipants administered a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
Concomitant group (V116 + QIV followed by placebo)EXPERIMENTALParticipants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
Sequential group (placebo + QIV followed by V116)EXPERIMENTALParticipants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30
V116 Lot 1EXPERIMENTALParticipants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
V116 Lot 2EXPERIMENTALParticipants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
V116 Lot 3EXPERIMENTALParticipants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
Cohort 1 V116EXPERIMENTALPneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.
Cohort 1 PCV20ACTIVE_COMPARATORPneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.
Cohort 2 V116EXPERIMENTALPneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.
Cohort 2 PCV20ACTIVE_COMPARATORPneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.
Cohort 1: V116EXPERIMENTALParticipants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
Cohort 1: PCV15ACTIVE_COMPARATORParticipants will receive a single 0.5 mL IM injection of PCV15 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
Cohort 2: V116EXPERIMENTALParticipants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
Cohort 2: PPSV23ACTIVE_COMPARATORParticipants will receive a single 0.5 mL IM injection of PPSV23 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
Cohort 3: V116EXPERIMENTALParticipants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV15, PCV20, PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 prior to the enrollment.
PNEUMOVAX™23ACTIVE_COMPARATORParticipants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.
Phase 1: V116 0.5 mLEXPERIMENTALParticipants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
Phase 1: V116 1.0 mLEXPERIMENTALParticipants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
Phase 1: Pneumovax™23ACTIVE_COMPARATORParticipants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
Phase 2: V116EXPERIMENTALParticipants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
Phase 2: Pneumovax™23ACTIVE_COMPARATORParticipants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2

Interventions

NameTypeDescription
V116BIOLOGICALPneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PPSV23BIOLOGICALPneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
PlaceboBIOLOGICALSaline in each 0.5 mL sterile solution
PCV15BIOLOGICALPneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
QIVBIOLOGICALSingle 0.5 mL IM injection
Matching Placebo for V116BIOLOGICALSingle 0.5 mL of sterile saline IM injection
PCV15 - Part BBIOLOGICALPneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
PCV20BIOLOGICAL0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
PNEUMOVAX™23BIOLOGICALPneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Unlock Study Design Details

Eligibility Criteria

Age Range2 Years to 17 Years
SexALL
Healthy VolunteersNo
Study Sites92

Inclusion Criteria: * Has a diagnosis and stable medical management (for at least 3 months) of one of the following risk conditions for pneumococcal disease: Diabetes mellitus, chronic compensated liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease. * Has completed...

Countries:United StatesCanadaChileColombiaFinlandFranceIsraelJapanPolandSpainSwedenThailandTurkey (Türkiye)AustraliaNew ZealandSouth KoreaArgentinaGermanyTaiwanUnited KingdomAustriaDenmarkBelgiumSouth AfricaPuerto RicoItaly
Unlock Eligibility Criteria

Frequently asked questions about V116

What is V116 used for?

V116 is an investigational monoclonal antibody being developed for the prevention of pneumococcal disease, including pneumonia and pneumococcal infection. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.

Who makes V116?

V116 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting Phase 3 clinical trials to evaluate the safety and immunogenicity of V116 in various adult populations.

What phase is V116 in?

V116 is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. Four Phase 3 trials have been completed, with a total enrollment of 4,409 participants.

What clinical trials is V116 in?

V116 has completed four Phase 3 trials: NCT05393037 in adults with HIV, NCT05464420 in adults 18-49 years, NCT05569954 in vaccine-naive adults 50 years or older, and NCT05633992 in vaccine-naive Japanese older adults. All trials evaluated safety and immunogenicity against pneumococcal disease.

How does V116 work?

V116 is a monoclonal antibody designed to target pneumococcal disease. As an antibody, it is intended to provide passive immunity by binding to pneumococcal bacteria or their components, potentially preventing infection. However, the specific molecular target has not been disclosed in available information.